Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 6/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611174 | 0.90 | LMNA (0.55) | LMNAIDO1PLA2G4ACNR2ATM | |
| SCHEMBL18611274 | 0.81 | TNF (0.42) | LMNAPLA2G4ACNR2MEN1KMT2A | |
| SCHEMBL17023679 | 0.80 | KRAS (0.50) | LMNAIDO1MEN1KMT2ACFD | |
| SCHEMBL17023688 | 0.79 | CFD (0.49) | LMNAIDO1CNR2MEN1KMT2A | |
| SCHEMBL26879516 | 0.79 | LMNA (0.67) | LMNAIDO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18611010 | 0.76 | LMNA (0.53) | LMNAATMMEN1KMT2ACFD | |
| SCHEMBL18572850 | 0.76 | LMNA (0.55) | LMNAMEN1KMT2ACREBBPALDH1A1 | |
| SCHEMBL18591257 | 0.75 | LMNA (0.49) | LMNAIDO1CNR2MEN1KMT2A | |
| SCHEMBL19208616 | 0.75 | LMNA (0.54) | LMNAMEN1KMT2ACREBBPALDH1A1 | |
| SCHEMBL17034509 | 0.74 | PSEN1 (0.48) | PLA2G4ACNR2MEN1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065459-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065459-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | TFPI, CFD, F3 | LMNA 1587/4885IDO1 618/4885PLA2G4A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.